Vergote I - Search Results

1

Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.

Neven P, Van Calster B, Van den Bempt I, Van Huffel S, Van Belle V, Hendrickx W, Decock J, Wildiers H, Paridaens R, Amant F, Leunen K, Berteloot P, Timmerman D, Van Limbergen E, Weltens C, Van den Bogaert W, Smeets A, Vergote I, Christiaens MR, Drijkoningen M. Neven P, et al. Among authors: vergote i. Breast Cancer Res Treat. 2008 Jul;110(1):153-9. doi: 10.1007/s10549-007-9687-4. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687649

2

Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature.

Timmerman D, Moerman P, Vergote I. Timmerman D, et al. Among authors: vergote i. Gynecol Oncol. 1995 Dec;59(3):405-8. doi: 10.1006/gyno.1995.9952. Gynecol Oncol. 1995. PMID: 8522265 Review.

3

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.

Assikis VJ, Neven P, Jordan VC, Vergote I. Assikis VJ, et al. Among authors: vergote i. Eur J Cancer. 1996 Aug;32A(9):1464-76. doi: 10.1016/0959-8049(96)00184-0. Eur J Cancer. 1996. PMID: 8911103 Review.

4

Images in clinical medicine. Tamoxifen-induced endometrial polyp.

Timmerman D, Vergote I. Timmerman D, et al. Among authors: vergote i. N Engl J Med. 1996 Nov 28;335(22):1650. doi: 10.1056/NEJM199611283352205. N Engl J Med. 1996. PMID: 8929362 Free article. No abstract available.

5

The feasibility of open laparoscopy in gynecologic-oncologic patients.

Decloedt J, Berteloot P, Vergote I. Decloedt J, et al. Among authors: vergote i. Gynecol Oncol. 1997 Jul;66(1):138-40. doi: 10.1006/gyno.1997.4738. Gynecol Oncol. 1997. PMID: 9234934 Clinical Trial.

6

Should tamoxifen users be screened for endometrial lesions?

Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Lancet. 1998 Jan 17;351(9097):155-7. doi: 10.1016/S0140-6736(05)78216-7. Lancet. 1998. PMID: 9449866 No abstract available.

7

Controversies regarding tamoxifen and uterine carcinoma.

Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Curr Opin Obstet Gynecol. 1998 Feb;10(1):9-14. doi: 10.1097/00001703-199802000-00003. Curr Opin Obstet Gynecol. 1998. PMID: 9484623 Review.

8

Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen.

Dal Cin P, Timmerman D, Van den Berghe I, Wanschura S, Kazmierczak B, Vergote I, Deprest J, Neven P, Moerman P, Bullerdiek J, Van den Berghe H. Dal Cin P, et al. Among authors: vergote i. Cancer Res. 1998 Jun 1;58(11):2278-81. Cancer Res. 1998. PMID: 9622058

9

A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen.

Timmerman D, Deprest J, Bourne T, Van den Berghe I, Collins WP, Vergote I. Timmerman D, et al. Among authors: vergote i. Am J Obstet Gynecol. 1998 Jul;179(1):62-70. doi: 10.1016/s0002-9378(98)70294-7. Am J Obstet Gynecol. 1998. PMID: 9704766 Clinical Trial.

10

Gastrostomy using a "Gastrofix" as an alternative for nasogastric tubes in ovarian cancer surgery.

Amant F, Berteloot P, Vergote I. Amant F, et al. Among authors: vergote i. Gynecol Oncol. 1998 Dec;71(3):348-51. doi: 10.1006/gyno.1998.5216. Gynecol Oncol. 1998. PMID: 9887229

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

874 results

Search Page